First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia
Authors:
- D ReaDRD Rea
- G EtienneGEG Etienne
- F NicoliniFNF Nicolini
- P Cony-MakhoulPCP Cony-Makhoul
- H Johnson-AnsahHJH Johnson-Ansah
- L LegrosLLL Legros
- F HuguetFHF Huguet
- M TulliezMTM Tulliez
- M GardembasMGM Gardembas
- K BouabdallahKBK Bouabdallah
- P RousselotPRP Rousselot
- J-M CayuelaJCJ-M Cayuela
- 30 March 2012
- journal article
- Published by Springer Nature in Leukemia
- Vol. 26 (10) , 2254-2259
Abstract
Imatinib mesylate is the sole BCR-ABL tyrosine kinase inhibitor approved as first-line treatment of accelerated-phase (AP) chronic myeloid leukemia (CML). Indication was based on the STI571 0109 study, in which imatinib favorably compared to historical treatments in patients failing prior therapies. The relevance of these results to currently newly diagnosed AP-CML patients remains unknown. We evaluated the benefit of imatinib in 42 newly diagnosed AP-CML patients. In all, 16 patients had hematological acceleration without chromosomal abnormalities in addition to the Philadelphia chromosome (ACAs; HEM-AP), 16 solely had ACAs (ACA-AP) and 10 had hematological acceleration plus ACAs (HEM-AP + ACA). Major cytogenetic responses were achieved in 93.7% of HEM-AP patients, 75% of patients with ACA-AP (P=NS) and 40% of patients with HEM-AP + ACA (P=0.0053). The 24-month failure-free survival rate was 87.5% in HEM-AP patients, 43.8% in ACA-AP patients and 15% in HEM-AP + ACA patients (P=0.022). The 24-month estimate of progression-free survival was 100% in HEM-AP patients, 92.8% in ACA-AP patients and 58.3% in HEM-AP + ACA patients (P=0.0052). In conclusion, frontline imatinib allows favorable outcomes in HEM-AP and ACA-AP patients but appears insufficient for patients with HEM-AP + ACA. Broader-target and/or more potent BCR-ABL tyrosine kinase inhibitors alone or in combination may be considered in this setting.Keywords
This publication has 20 references indexed in Scilit:
- Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNetJournal of Clinical Oncology, 2009
- Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trialsHaematologica, 2009
- Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetBlood, 2006
- Staging of chronic myeloid leukemia in the imatinib eraCancer, 2006
- Survival benefit with imatinib mesylate therapy in patients with accelerated‐phase chronic myelogenous leukemia—Comparison with historic experienceCancer, 2005
- Clinical and epidemiologic burden of chronic myelogenous leukemiaExpert Review of Anticancer Therapy, 2004
- Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 studyBlood, 2002
- The Biology of Chronic Myeloid LeukemiaNew England Journal of Medicine, 1999
- Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemiaBlood, 1988
- Characteristics of accelerated disease in chronic myelogenous leukemiaCancer, 1988